ライフサイエンスコーパス: poloxamer

1 estored to normal upon direct application of poloxamer.

2 crisis resolution was increased by purified poloxamer 188 (65/126 [52%] vs 45/123 [37%]; P =.02).

3 tial, and evaluate the potential benefits of Poloxamer 188 (P-188) in improving mitochondrial quality

4 el muscle cell, were subjected to short-term Poloxamer 188 (P188) and PEO(181) (8,000 g/mol) treatmen

5 repair acutely with the non-ionic surfactant poloxamer 188 (P188) restored cell viability to control

6 The mechanism by which poloxamer 188 (P188) seals a damaged cell membrane is ex

7 Subsequent studies using Poloxamer 188 (P188), a membrane resealing reagent, demo

8 Poloxamer 188 (P188), a non-ionic triblock copolymer, ha

9 the cells were treated with the FDA-approved poloxamer 188 (P188).

10 20 and 80 (PS20 and PS80, respectively) and poloxamer 188 (P188).

11 These findings suggest that poloxamer 188 adsorbs into the lipid bilayers, thereby d

12 .0% of Compritol(R) 888 ATO (lipid), 1.5% of poloxamer 188 and 0.1% of the cationic polymer poly(ally

13 and that application of the membrane sealant poloxamer 188 corrects these defects in vitro.

14 Among children and adults with SCD, poloxamer 188 did not significantly shorten time to last

15 s indicated an even more pronounced purified poloxamer 188 effect in children aged 15 years or younge

16 These findings do not support the use of poloxamer 188 for vaso-occlusive episodes.

17 Adverse events that were more common in the poloxamer 188 group than the placebo group included hype

18 cipants younger than 16 years (88.7 h in the poloxamer 188 group vs 71.9 h in the placebo group; diff

19 t dose of parenteral opioids (81.8 h for the poloxamer 188 group vs 77.8 h for the placebo group; dif

20 g to optimal dosing and long-term effects of poloxamer 188 in humans have been resolved, chemical-bas

21 fety and efficacy of adjunctive therapy with poloxamer 188 in patients receiving thrombolytic therapy

22 A 1-hour 100-mg/kg loading dose of poloxamer 188 intravenously followed by a 12-hour to 48-

23 Purified poloxamer 188 may increase tissue oxygenation and thereb

24 c administration, and time to treatment with poloxamer 188 or placebo.

25 omized 114 patients to a 48-hour infusion of poloxamer 188 or vehicle placebo beginning immediately a

26 A previous phase 3 trial of poloxamer 188 reported shortened duration of painful vas

27 Adjunctive therapy with poloxamer 188 resulted in substantial benefit in this ra

28 In vivo administration of poloxamer 188 to dystrophic mice instantly improved vent

29 First, addition of a poloxamer 188 to nanoparticle formulations increased upt

30 Poloxamer 188 treatment also resulted in a reduced incid

31 Although the mechanisms are unproven, poloxamer 188 treatment may accelerate thrombolysis, red

32 Furthermore, addition of poloxamer 188 was found to reduce the membrane capacitan

33 Poloxamer 188 was well tolerated without adverse hemodyn

34 xo Wellcome Inc, Research Triangle Park, NC; poloxamer 188) Injection is a nonionic surfactant with h

35 RheothRx (poloxamer 188) is a surfactant with hemorheological and

36 receive an intravenous infusion of purified poloxamer 188, 100 mg/kg for 1 hour followed by 30 mg/kg

37 33 (41) hours in those treated with purified poloxamer 188, a 9-hour reduction (P =.04).

38 nic block co-polymeric surface active agent, poloxamer 188, on electroporation of artificial lipid me

39 articles (CGT-NP) prepared using gelatin and Poloxamer 188-grafted heparin copolymer demonstrated sig

40 bFGF-loaded NP (bFGF-NP) were prepared with Poloxamer 188-grafted heparin copolymer using water-in-w

41 charge pulse and voltage clamp experiments, poloxamer 188-treated membranes exhibited a statisticall

42 Also, poloxamer 188-treated membranes were found to have a rel

43 Poloxamer 188-treated patients demonstrated a 38% reduct

44 the symptoms were observed when the purified poloxamer 188-treated patients were compared with the pa

45 lipid bilayer of the type that are sealed by poloxamer 188.

46 eversed using the membrane sealant copolymer poloxamer 188.

47 membranes and membranes treated with 1.0 mM poloxamer 188.

48 crog/ml), poloxamine 908 (10-400 microg/ml), poloxamer 402 (20-400 microg/ml), and poloxamer 407 (10-

49 g/ml), poloxamer 402 (20-400 microg/ml), and poloxamer 407 (10-400 microg/ml).

50 established a novel mice model of HTG-AP by poloxamer 407 (P-407) combined with caerulein (Cae).

51 porous silicon (pSi) particles embedded in a poloxamer 407 (P407) hydrogel matrix.

52 These PNPs were then incorporated into Poloxamer 407 (P407) hydrogels and utilized as an inert

53 ic tetracaine (T) is attached to the polymer poloxamer 407 (P407) via a photo-cleavable coumarin link

54 An X-ray imageable poloxamer 407 (POL)-based drug delivery gel was develope

55 secretion, we injected the lipase inhibitor poloxamer 407 alone or before oral lipid gavage.

56 Eight patients showed cross-sensitization to poloxamer 407 and 3 to polysorbate 80.

57 followed by suspension in a solution of 17% poloxamer 407 to obtain O2L-001.

58 Cross-sensitization to polysorbate 80 and poloxamer 407 was assessed.

59 on an in-situ gel formulation created using Poloxamer 407, Carbopol 940, and Hydroxy Propyl Methyl C

60 vel method based on a biocompatible polymer, poloxamer 407, which could significantly increase the vi

61 Poloxamer 407-coated nanocrystals containing the proteas

62 The optimized formulation was tested in poloxamer 407-induced hyperlipidemic rats.

63 S) intake from Aureobasidium pullulans using poloxamer-407 (PX-407) induced type 2 diabetes mellitus

64 Poly(ethylene oxide) (PEO) and poloxamers, a class of poly(ethylene oxide)-b-poly(propy

65 Poloxamers, a class of synthetic triblock copolymers, ar

66 esults showed that application of virus with poloxamer alone resulted in diffuse epicardial gene tran

67 hilic block copolymers based on PEO and PPO (Poloxamers and Pluronics) and advances in the area of PE

68 Poloxamers and poloxamine nonionic surfactants have dive

69 for quantitative determination of Pluronic (poloxamer) and Tetronic (poloxamine) macromolecules.

70 pylene oxide)-poly(ethylene oxide) (known as poloxamers) are typical examples of thermosensitive poly

71 A thermosensitive poloxamer-based gel for drug delivery was developed that

72 Here, we show that Pluronic (Poloxamer) block copolymers are amenable to low-temperat

73 oxide) (PEO)-poly(propylene oxide) (PPO)-PEO poloxamers, capable of controlled release of a therapeut

74 suitable for nasal administration, including poloxamer, chitosan, EHEC, xyloglucan, Carbopol, gellan

75 Poloxamer compositions released GM-0111 cargo within 1 h

76 rdiac myocyte mechanical compliance and that poloxamer confers a highly effective membrane-stabilizin

77 immune responses and that is formulated with poloxamer CRL1005 and benzalkonium chloride to enhance i

78 tein B and phosphoprotein 65 formulated with poloxamer CRL1005 and benzalkonium chloride.

79 study to evaluate the safety and efficacy of poloxamer, formulated as RheothRx Injection, in 50 patie

80 al vectors to the epicardial surface, use of poloxamer gel to increase virus contact time, and mild t

81 Since poloxamers have been shown to rescue damaged cells, the

82 bio-adhesion and longer residence time than Poloxamer hydrogels currently being investigated clinica

83 immune responses comparable to biocompatible Poloxamer hydrogels, yet they released payloads at a ~5-

84 release and longer delivery time compared to Poloxamer hydrogels.

85 d is demonstrated by the analysis of various poloxamers, i.e., poly(ethylene oxide) (PEO)-poly(propyl

86 In our recent report, we have developed a poloxamer-PLGA nanoformulation loaded with elvitegravir

87 insertion above 22 mN/m further suggests the poloxamer selectively adsorbs into damaged portions of e

88 reduction was likely to be that the viscous poloxamer solution blocked convection of viral vectors i

89 dy is to evaluate the efficacy of a specific poloxamer, surfactant polymer dressing (SPD), which is c

90 wn that chronic infusion of membrane-sealing poloxamer to severely affected dystrophic dogs reduced m

91 ormed on 23 membranes with 10 control and 13 poloxamer-treated membranes, and voltage pulse experimen

92 ments on 49 membranes with 26 control and 23 poloxamer-treated membranes.

93 Interestingly, after chronic poloxamer treatment, the poor compliance of isolated can

94 Investigational variables included poloxamer use, trypsin concentration, and safety.

95 ng a mechanism for the cell to be rid of the poloxamer when the membrane is restored.